Kenneth A Brameld from Hillsborough, CA, age 53

Heterocyclic Antiviral Compounds
view source
US Patent:

8273773, Sep 25, 2012
Filed:

Jul 22, 2009
Appl. No.:

12/460658
Inventors:

Kenneth Albert Brameld - Palo Alto CA, US
David Scott Carter - Sunnyvale CA, US
Elbert Chin - San Jose CA, US
Javier de Vicente Fidalgo - Mountain View CA, US
Jim Li - San Francisco CA, US
Ryan Craig Schoenfeld - San Jose CA, US
Eric Brian Sjogren - Mountain View CA, US
Francisco Xavier Talamas - Mountain View CA, US
Assignee:

Roche Palo Alto LLC - South San Francisco CA
International Classification:

A61K 31/4412
C07D 213/64
US Classification:

514345, 514344, 514348, 514351, 546288, 546290, 546296, 546300, 546301, 546302, 546303
Abstract:

Compounds having the formula I wherein R, R, R, R, R, R, R, R, Rand n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Antiviral Agents
view source
US Patent:

20070287699, Dec 13, 2007
Filed:

Apr 30, 2007
Appl. No.:

11/742461
Inventors:

Dange Kumar - Salt Lake City UT, US
Roopa Rai - San Carlos CA, US
Wendy Young - San Mateo CA, US
Huiyong Hu - San Diego CA, US
Jennifer Riggs - Cardiff by the Sea CA, US
Tony Ton - Fremont CA, US
Michael Green - Half Moon Bay CA, US
Barry Hart - Palo Alto CA, US
Kenneth Brameld - San Mateo CA, US
Jeffrey Dener - Millbrae CA, US
Assignee:

ViroBay, Inc. - Menlo Park CA
International Classification:

A61K 31/4709
A61K 31/496
A61K 31/5355
A61K 31/541
A61K 31/551
A61P 31/14
C07D 215/233
C07D 243/08
C07D 279/12
C07D 401/04
C07D 413/04
C07D 455/02
C07D 471/04
US Classification:

514218000, 514228200, 514234500, 514235200, 514253080, 514300000, 514306000, 514312000, 540575000, 544128000, 544238000, 544058200, 546123000, 546138000, 546156000
Abstract:

Compounds are provided having utility for the treatment of viral infections, particularly HCV.

Benzoxazine Derivatives As Crac Modulators
view source
US Patent:

20130090333, Apr 11, 2013
Filed:

Sep 25, 2012
Appl. No.:

13/626117
Inventors:

Kenneth Albert Brameld - Menlo Park CA, US
Joshua Kennedy-Smith - New York NY, US
Assignee:

Hoffmann-La Roche Inc. - Nutley NJ
International Classification:

A61K 31/538
C07D 413/10
A61P 11/06
C07D 417/14
A61P 19/02
A61P 11/00
C07D 265/36
C07D 413/14
US Classification:

5142305, 544105
Abstract:

Compounds of the formula (I):or pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

Azabenzoxazine Derivatives As Crac Modulators
view source
US Patent:

20130090334, Apr 11, 2013
Filed:

Sep 25, 2012
Appl. No.:

13/626128
Inventors:

Kenneth Albert Brameld - Menlo Park CA, US
Joshua Kennedy-Smith - New York NY, US
Assignee:

Hoffmann-La Roche Inc - Nutley NJ
International Classification:

C07D 498/04
US Classification:

5142305, 544105
Abstract:

Compounds of the formula (I):or pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

Azaindole Derivatives As Tyrosine Kinase Inhibitors
view source
US Patent:

20140073626, Mar 13, 2014
Filed:

May 16, 2012
Appl. No.:

14/117885
Inventors:

Kenneth Albert Brameld - Menlo Park CA, US
Erik Verner - Belmont CA, US
Assignee:

Principia Biopharma - South San Francisco CA
International Classification:

C07D 487/04
A61K 31/5377
A61K 45/06
A61K 31/4985
US Classification:

51421018, 544350, 514249, 544117, 5142342
Abstract:

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

Quinolone Derivatives As Fibroblast Growth Factor Inhibitors
view source
US Patent:

20210292323, Sep 23, 2021
Filed:

May 3, 2021
Appl. No.:

17/306528
Inventors:

- South San Francisco CA, US
Kenneth Albert Brameld - Menlo Park CA, US
Assignee:

Principia Biopharma Inc. - South San Francisco CA
International Classification:

C07D 471/04
A61K 31/519
A61K 45/06
C07D 519/00
A61K 31/5377
C07D 487/04
Abstract:

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Spirocyclic Compounds As Tryptophan Hydroxylase Inhibitors
view source
US Patent:

20210205305, Jul 8, 2021
Filed:

Mar 15, 2021
Appl. No.:

17/201750
Inventors:

- Basel, CH
Daniel R. Goldberg - Seattle WA, US
Kenneth Brameld - Menlo Park CA, US
Eric Brian Sjogren - Mountain View CA, US
Andrew Scribner - Durham NC, US
Assignee:

Altavant Sciences GmbH - Basel
International Classification:

A61K 31/506
C07D 471/10
C07D 519/00
A61K 9/00
Abstract:

The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Immunoproteasome Inhibitors
view source
US Patent:

20200277312, Sep 3, 2020
Filed:

Nov 14, 2018
Appl. No.:

16/764136
Inventors:

- South San Francisco CA, US
Timothy Duncan Owens - Redwood City CA, US
Kenneth Albert Brameld - Menlo Park CA, US
David Michael Goldstein - Redwood City CA, US
International Classification:

C07F 5/02
Abstract:

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.